Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Atopic Immunoglobulin E-Mediated Allergic Disorder
Interventions: STMC-103H, Placebo; Biological
Lead sponsor: Siolta Therapeutics, Inc.; Industry
Eligibility: 2 Years to 40 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Stockton, California • Tustin, California

Conditions: Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Mantle Cell Lymphoma (MCL), Richter's Syndrome, T-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma, Myeloid Malignancies, Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome (MDS), MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome
Interventions: PRT2527, Zanubrutinib, Venetoclax; Drug
Lead sponsor: Prelude Therapeutics Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 5
States / cities: Duarte, California • Bethesda, Maryland • Boston, Massachusetts + 2 more

Conditions: Pediculosis
Interventions: Malathion gel 0.5%, Permethrin 1% rinse (Nix Crème); Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 7
States / cities: Hot Springs, Arkansas • Sacramento, California • Kissimmee, Florida + 4 more

Conditions: Epilepsy
Interventions: Brivaracetam tablets, Brivaracetam bolus, Brivaracetam infusion, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Lexington, Kentucky + 5 more

Conditions: Breast Cancer
Interventions: Zoledronic acid, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 92
States / cities: Anchorage, Alaska • Hot Springs, Arkansas • Springdale, Arkansas + 81 more

Conditions: Allergic Conjunctivitis
Interventions: AC-170 0.24%, AC-170 0%; Drug
Lead sponsor: Aciex Therapeutics, Inc.; Industry
Eligibility: 10 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Moderate Risk of CVD
Interventions: Aspirin (Acetylsalicylic acid, BAYE4465), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 55 Years and older
Enrollment: 12,546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 73
States / cities: Birmingham, Alabama • Graysville, Alabama • Pell City, Alabama + 67 more

Conditions: Essential Thrombocythemia
Interventions: Bomedemstat; Drug
Lead sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 7
States / cities: Jacksonville, Florida • Ann Arbor, Michigan • New York, New York + 4 more

Conditions: Multiple Sclerosis, Pathologic Processes, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Demyelinating Diseases, Autoimmune Diseases, Immune System Diseases
Interventions: Music Training Intervention, Music Listening; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 80 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Alzheimer Disease, Dementia Alzheimers, Dementia of Alzheimer Type
Interventions: EHR CDS, Usual Care; Behavioral · Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diverticulum, Colon, Colorectal Neoplasms, Crohn Disease, Colitis, Ulcerative, Colostomy, Ileostomy - Stoma, Rectal Prolapse, Intestinal Polyposis, Lymphoma, Endometriosis, Intestinal Volvulus
Interventions: Not listed
Lead sponsor: novoGI; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Atlamonte Springs, Florida • Port Charlotte, Florida • Springfield, Missouri

Conditions: Alzheimer's Disease
Interventions: BPN14770, Placebo; Drug
Lead sponsor: Tetra Discovery Partners; Industry
Eligibility: 25 Years to 90 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Degenerative Disc Disease
Interventions: MagnetOs Flex Matrix; Device
Lead sponsor: Research Source; Network
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Southfield, Michigan

Conditions: Osteoarthritis
Interventions: GSK3196165, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Miami, Florida • Duncansville, Pennsylvania

Conditions: Clostridium Difficile Infection Recurrence
Interventions: RBX2660; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 12
States / cities: North Little Rock, Arkansas • Camarillo, California • Hamden, Connecticut + 9 more

Conditions: Cognitive Disorders
Interventions: SUVN-D4010, Placebo; Drug
Lead sponsor: Suven Life Sciences Limited; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Diabetic Foot Ulcer, Diabetic Foot
Interventions: Medaxis Debritom+, Sharp Surgical Debridement, Additional Outer Dressing Application, Offloading, Fibracol Wound Dressing; Other
Lead sponsor: Medaxis, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 6
States / cities: San Francisco, California • South Miami, Florida • Frederick, Maryland + 3 more

Conditions: Alzheimer Disease
Interventions: bapineuzumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 16
States / cities: Phoenix, Arizona • Encino, California • Delray Beach, Florida + 11 more

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab Pegol, Placebo, Methotrexate; Biological · Other
Lead sponsor: UCB Pharma SA; Industry
Eligibility: 18 Years and older
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 70
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 63 more

Conditions: Adult Acute Myeloid Leukemia in Remission, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Myelodysplastic Syndrome, Childhood Renal Cell Carcinoma, Chronic Myelomonocytic Leukemia, Clear Cell Renal Cell Carcinoma, de Novo Myelodysplastic Syndrome, Metastatic Renal Cell Cancer, Previously Treated Myelodysplastic Syndrome, Progression of Multiple Myeloma or Plasma Cell Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Non-Hodgkin Lymphoma, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts, Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Renal Medullary Carcinoma, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Fludarabine Phosphate, Total-Body Irradiation, Peripheral Blood Stem Cell Transplantation, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Mycophenolate Mofetil; Drug · Radiation · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 8
States / cities: Tucson, Arizona • Stanford, California • Atlanta, Georgia + 5 more

Conditions: Ischemic Stroke, Malignant Edema
Interventions: Glyburide for Injection, Placebo; Drug
Lead sponsor: Remedy Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 17
States / cities: Tucson, Arizona • Stanford, California • New Haven, Connecticut + 14 more

Conditions: Ovarian Cancer
Interventions: BSI-201; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Sclerosis
Interventions: BeCare Mobile App; Device
Lead sponsor: BeCare Link LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Rhinitis
Interventions: RhinAer ARC Stylus; Device
Lead sponsor: Aerin Medical; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 129 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 12
States / cities: Goodyear, Arizona • Roseville, California • San Francisco, California + 9 more

Search by objective public record fields.

A Phase 1b Study of STMC-103H in Multi-Sensitized Allergic Subjects Who Are Otherwise Healthy

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice

Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy

Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer

A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease

Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)

Music-4-MS to Improve Cognition in People Living With Multiple Sclerosis: A Feasibility Study

An Electronic Clinical Decision Support Tool to Reduce Low-value Antipsychotic Prescriptions

A RETROspective Data Collection of comPRESSion Anastomosis Using the ColonRing

A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects

Study to Assess the Performance of MagnEtOs Flex Matrix Compared to Cellular Allograft

A Study to Investigate the Efficacy and Safety of GSK3196165 in Inflammatory Hand Osteoarthritis

A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects

A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot

Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis

Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer

Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Patient Centered Outcomes Analysis for MS Using a Mobile Application

A Study of RhinAer ARC Stylus for Treating Chronic Rhinitis (RELIEF)